Trump announces 100% chip tariff as Apple ups U.S. investment
Tharimmune, Inc. (NASDAQ:THAR) Chief Executive Officer Sireesh Appajosyula reported purchasing shares of the company’s common stock on June 20, 2025. The transactions involved the acquisition of 61,496 shares at prices ranging from $1.42 to $1.48, totaling $90,972. The stock currently trades at $1.31, below the CEO’s purchase price, in a company with a market capitalization of just $3.6 million.
According to a Form 4 filing with the Securities and Exchange Commission, Appajosyula acquired 60,806 shares at $1.48 and 690 shares at $1.42. Following these transactions, Appajosyula directly owns 64,868 shares of Tharimmune. InvestingPro analysis shows the company maintains more cash than debt on its balance sheet, though analysts project continued losses for the year. The stock’s analyst target price of $5 suggests significant potential upside, with additional insights available through InvestingPro’s comprehensive analysis tools.
In other recent news, Tharimmune, Inc. has unveiled significant leadership changes and advancements in its drug development pipeline. The company has appointed Sireesh Appajosyula as the new Chief Executive Officer, succeeding Randy Milby, who stepped down due to personal reasons. In conjunction with this change, Vincent LoPriore has been named Executive Chairman, bringing over 30 years of investment banking experience to the role. Tharimmune also announced the addition of two new directors, Clay Kahler and Gary Stetz, to its Board, as Leonard Mazur and Lynne Bui prepare to depart.
In terms of drug development, Tharimmune has reported promising Phase 1 study results for TH104, a drug designed for opioid exposure prophylaxis. The study showed that TH104 has a unique metabolic profile and comparable safety to intravenous nalmefene, receiving positive feedback from the FDA. This could allow Tharimmune to submit a New Drug Application without further clinical trials. The company’s pipeline also includes therapies for chronic pruritus and autoimmune diseases, along with a multispecific biologic platform targeting solid tumors. These developments reflect Tharimmune’s ongoing efforts to advance its clinical programs and strengthen its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.